 Rituximab
"Rituximab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS.
| Descriptor ID |
D000069283
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.075.785 D12.776.124.790.651.114.224.075.785 D12.776.377.715.548.114.224.284.785
|
| Concept/Terms |
Rituximab- Rituximab
- CD20 Antibody, Rituximab
- Rituximab CD20 Antibody
|
Below are MeSH descriptors whose meaning is more general than "Rituximab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.124.486.485.114.224.075]
- Rituximab [D12.776.124.486.485.114.224.075.785]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.124.790.651.114.224.075]
- Rituximab [D12.776.124.790.651.114.224.075.785]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.377.715.548.114.224.284]
- Rituximab [D12.776.377.715.548.114.224.284.785]
Below are MeSH descriptors whose meaning is more specific than "Rituximab".
This graph shows the total number of publications written about "Rituximab" by people in this website by year, and whether "Rituximab" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2004 | 0 | 2 | 2 | | 2006 | 0 | 2 | 2 | | 2007 | 0 | 7 | 7 | | 2008 | 0 | 3 | 3 | | 2009 | 0 | 7 | 7 | | 2010 | 0 | 5 | 5 | | 2011 | 0 | 9 | 9 | | 2012 | 0 | 4 | 4 | | 2013 | 0 | 9 | 9 | | 2014 | 0 | 8 | 8 | | 2015 | 0 | 4 | 4 | | 2016 | 3 | 4 | 7 | | 2017 | 0 | 7 | 7 | | 2018 | 1 | 2 | 3 | | 2019 | 4 | 6 | 10 | | 2020 | 7 | 6 | 13 | | 2021 | 2 | 12 | 14 | | 2022 | 1 | 10 | 11 | | 2023 | 0 | 6 | 6 | | 2024 | 3 | 7 | 10 | | 2025 | 3 | 7 | 10 |
To return to the timeline, click here.
Below are the most recent publications written about "Rituximab" by people in Profiles.
-
Sharma S, Ali R, Bouska A, Jochum D, Kesireddy M, Mahov S, Lownik J, Zhang W, Lone W, Soma MA, Gamboa A, Devarakonda V, El-Gamal D, Fariha A, Mansoor A, Stewart D, Martin P, Link BK, Advani RH, Barr PM, Goy AH, Mehta A, Kamdar M, Stephens DM, Bachanova V, Smith L, Morin R, Pararajalingam P, Lunning MA, Fu K, Weisenburger D, Chan WC, Khoury J, Greiner TC, Vose JM, Merchant A, Bi C, Iqbal J. Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma. Nat Commun. 2025 Nov 05; 16(1):9762.
-
Hess B, Moskowitz A, Davis JA, Strati P, Sawalha Y, Bakos J, Sorrell M, Ferreira AC, Escribano-Serrat S, De Castro M, Brooks TR, Hill BT, Shah GL, Falade AS, Merryman R, Kamdar M, Ip A, Nachar V, Bennett JG, Lux N, Ahmed N, Hoffmann M, LaCasce A. Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R. Haematologica. 2026 Apr 01; 111(4):1389-1395.
-
Hua LH, Brown B, Camacho E, Chinea AR, Greenberg BM, Henry RG, Houtsma E, Moreo N, Alvarez E. Switch from intravenous anti-CD20 therapy to subcutaneous ofatumumab in patients with relapsing MS: results from the OLIKOS study. J Neurol. 2025 Oct 24; 272(11):725.
-
Mondello P, Negaard B, Feldman AL, Link BK, Casulo C, Chihara D, Russler-Germain D, Romancik J, Gribbin C, Haddadi S, Mou E, Micallef IN, Johnston PB, Novak J, Wang Y, King RL, Novak AJ, Habermann TM, Martin P, Kahl B, Nowakowski GS, Nastoupil LJ, Cerhan JR, Flowers CR, Lossos IS, Burack RW, Maurer MJ, Ansell SM. Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohorts. Blood Cancer J. 2025 Aug 08; 15(1):134.
-
Porche K, King RL, Habermann TM, Johnston PB, Spinner RJ. Low-Grade B-Cell Neurolymphomatosis: A Case Series and Diagnostic Insight. World Neurosurg. 2025 Sep; 201:124260.
-
van Dooren HJ, van Schaik M, Dorjée AL, Arends EJ, Mackay M, Cooney L, Fox DA, Wofsy D, Smilek D, Aranow C, Dall'Era M, Huizinga TWJ, van Kooten C, Toes REM, Diamond B, Teng YKO, Suurmond J. Differences in Dynamics of Specific Antinuclear Antibodies and Their Susceptibility to B Cell-Targeting Treatment in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2025 Nov; 77(11):1560-1572.
-
Denburg MR, Hirabayashi K, Davies AG, Razzaghi H, Dharnidharka VR, Dixon BP, Flynn JT, Gluck CA, Mitsnefes MM, Smoyer WE, Furth SL, Forrest CB. Utilization of anti-CD20 antibodies for treatment of childhood nephrotic syndrome, 2010 to 2022. Pediatr Nephrol. 2025 Oct; 40(10):3121-3127.
-
Assouline SE, Mehta A, Hanel W, Doucet S, Johnston PB, Danilov A, Cooper BW, Chudnovsky A, Ding J, Long T, Stroopinsky D, Berg D, Alinari L. Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2025 Nov; 25(11):788-799.e11.
-
Kim TM, Lakhani NJ, Soumerai J, Kamdar M, Gainor JF, Messersmith W, Fanning P, Guan S, Jin F, Forgie A, Wan HI, Pons J, Randolph SS, Kim WS. Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study. Haematologica. 2025 Sep 01; 110(9):2102-2112.
-
Deane KD, Holers VM, Emery P, Mankia K, El-Gabalawy H, Sparks JA, Costenbader KH, Schett G, van der Helm-van Mil A, van Schaardenburg D, Thomas R, Cope AP. Therapeutic interception in individuals at risk of rheumatoid arthritis to prevent clinically impactful disease. Ann Rheum Dis. 2025 Jan; 84(1):14-28.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|